Podcasts about HLA

Í hlaðvarpinu í dag ræða Ólafur og Andri um írönsku byltinguna árið 1979, þegar síðasti keisari Írans (sha) var steypt af stóli og stofnað var róttækt íslamskt lýðveldi undir klerkastjórn.Íranska byltingin var gífurlega afdrifaríkur atburður í nútímasögu Mið-Austurlanda. Ekki aðeins varð byltingin til þess að 2500 ára gömul stofnun íranska keisarans leið undir lok, heldur breyttist Íran á skömmum tíma úr einum helsta bandamanni Bandaríkjanna í Mið-Austurlöndum, í miðju Kalda stríðinu, yfir í mesta andstæðing Bandaríkjanna og vestrænnar heimsvaldastefnu á svæðinu. Byltingin sýndi einnig að pólitískt íslam og íslamismi breyddist um svæðið og hefur heldur betur sett svip sinn á Mið-Austurlönd síðustu áratugi. Keisarastjórn Mohammad Reza Pahlavi, frá því einræði hans var komið á eftir valdarán stutt af Vesturveldunum árið 1953, varð þekkt fyrir pólitíska kúgun og persónudýrkun, en einnig mikla tækni- menningarbyltingu í krafti gríðarlegs olíuauðs. Byltingin var sannkölluð fjöldahreyfing, ein sú vinsælasta í sögunni, en byltingarríkið undir stjórn Ayatollah Khomeini var einnig harðvíðtug og Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

Nesta aula, vamos desvendar as Síndromes Poliglandulares Autoimunes (SPA). Abordaremos a classificação completa, detalhando as características da SPA Tipo 1 (ligada ao gene AIRE), da SPA Tipo 2 (a mais comum, associada ao HLA) e de suas variantes. Endocrinologia descomplicada para médicos e residentes.Aqui você encontra conteúdos sobre atualização médica, casos clínicos e preparação para provas de título.

Host Anna Smith brings you a special episode of Girls On Film from the Mediterrane Film Festival in Malta, which this year celebrates 100 years of movie-making on the island. From Malta, Anna speaks with producer Susan Simnett, known for Brides, Chuck Chuck Baby, and Fadhia's Tree. She also chats to Euphoria star Barbie Ferreira, who received this year's Rising Star Award, and BAFTA-winning actor Monica Dolan, who presented at the festival's Golden Bee Awards. Back in the UK, broadcaster, film, TV and culture critic Ashanti Omkar joins Anna to discuss three powerful new films: Daisy-May Hudson and Sophie Compton's documentary Holloway, Athina Rachel Tsangari's medieval drama Harvest, and Claude Barras's stop-motion animation Savages. Harvest will be coming to UK cinemas on 18 July 2025. Keep an eye out for upcoming screenings of Holloway with Reclaim the Frame - championing intersectional feminist cinema across the UK. Check out their website for more details Savages will be released in the UK and Ireland on 1 August 2025. Find out more about the Mediterrane Film Festival on their website https://mediterrane.com/ Sign up to the Girls On Film newsletter here: http://eepurl.com/iEKaM-/ Or email girlsonfilmsocial@gmail.com to be signed up. Visit our new website www.girlsonfilm.org.uk Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Audio Editor: Cam Griffiths Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Whether you work in an HLA lab or rely on one for clinical services or care, you won't want to miss this episode of Coffee & Compatibility! James Robinson, founder of the bioinformation IPD-IMGT/HLA Database, joins us to share how this essential tool evolved into a global resource with over 74,000 submissions, 42,000+ alleles, and nearly 20 new entries every day!

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Í þættinum í dag fjalla Andri og Ólafur um langvarandi og blóðuga togstreitu Danmerkur og Svíþjóðar um yfirráð í Skandinavíu og við Eystrasalt, frá endalokum Kalmarsambandsins til Napóleonsstyrjaldanna.Stundum er sagt að fá ríki hafi háð jafn margar styrjaldir sín á milli og Danmörk og Svíþjóð. Á tímabilinu 1500–1800 háðu þau að minnsta kosti tíu stríð, með misjöfnum árangri, auk þess sem þau tóku þátt í þrjátíu ára stríðinu og stóðu andspænis öðrum rísandi stórveldum Evrópu. Danmörk var lengi valdamesta ríki Norðurlanda, en á 17. öld reis Svíþjóð til metorða og varð stórveldi við Eystrasaltið.Á 19. öld höfðu bæði Danmörk og Svíþjóð misst fyrri stöðu og þróuðust í smærri þjóðríki, undir áhrifum og þrýstingi stærri ríkja á borð við Rússland, Þýskaland, Bretland og Frakkland.Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

Gestir okkar í kvöld eru Benedikt Valsson og Fannar Sveinsson en þeir eru auðvitað betur þekktir undir brandinu “Hraðfrétta kóngarnir” en í dag eru þeir “Hlaðfrétta brósarnir”.Umræðuefni í þættinum:Fréttir vikunnarHlaðfréttirAlheimsdraumurinnHraðfréttirRiddaraspurningarKalda stríðiðÞessi þáttur er í boði:Ahyggjuleysi.is - afsláttur á Hero vélinni, ef þið segið að CAD sendi ykkur.WoltKaldiSaffran - 10 % afsláttur í appi með kóðanum CAD10Orka NáttúrunnarDineoutACROSjöstrand - 15 % afsláttur með kóðanum CADLengjanBúllanSubwayDave&JonsFrumherjiKEMINjótið vel kæru hlustendur.

Hlöðvar Hlaðvarp er farin í stutt sumarfrí. Meira síðar. 

Í þættinum í dag ræða Söguskoðunarbræður sögu páfadæmisins, þessa fornu stofnunar sem hefur gegnt lykilhlutverki í kristinni trú og evrópskri sögu öldum saman. Mögulega er páfadómurinn eitt elsta embætti sem enn er mannað í okkar heimshluta, og varla fór framhja neinum þegar nýr páfi var kjörinn nú fyrir skömmu. Í þessum þætti ræða Ólafur og Andri um þróun og sögu páfans, löggildingu hans sem arftaki Péturs postula, deilur hans við konunga og keisara á miðöldum, klofninginn við austurkirkjuna, siðaskiptin og fleira og fleira.Er hinn heilagi faðir í Róm arftaki Krists á jörðu, eða er hann afurð veraldlegra og pólitískra hreyfinga eftir fall Rómarveldis? Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

We're back in the French Riviera for a very special episode, as Girls On Film returns to the 78th edition of the Cannes Film Festival. This year, host Anna Smith welcomed guests to the second Girls On Film Cannes Do at The Members Club. This glamorous networking event on the beach brought together filmmakers, critics, and creatives celebrating the power of women in cinema. In this episode, you'll hear reflections from our community on what Girls On Film means to them. Later on in the episode Anna reunites with film journalist Wendy Ide who reflects on this year's films, which she says have been of a consistently high standard. Wendy shares her standout picks from the festival, from the fiercely divisive Die, My Love, a visceral exploration of the raw edges of motherhood and mental unravelling, to Sound of Falling, a haunting meditation on how trauma echoes through time and place. She also dives into Sirât, an allegorical road movie, in which gender and disability are refreshingly incidental, not defining. Plus other titles that are already generating serious awards buzz. And finally, we're joined by Liza van der Smissen and Nicole Lieberman, founders of the Female Film Club. This trailblazing global network uplifts women in the industry through practical workshops, seminars and a thriving, supportive community. They share the story behind their mission and how they're helping to reshape the future of film, one powerful connection at a time. They also unveil an exciting new opportunity: a £10,000 investment in a short film, designed to give back to their talented global community. To enter from 16th June onwards, filmmakers must join their networking space. If you're looking to join a space that champions and supports women in film, don't miss out – click this link to join the Female Film Club: [link: https://female-film-club.mn.co/users/onboarding/choose_plan?plan_id=1818474&bundle_token=aca8b4a8f139016aca1a9fdc680a97a8&utm_source=manual] We would also like to thank our incredible sponsors for all their support: Col Needham and Karen Needham at IMDb: [link: https://www.imdb.com/title/tt18211920/?ref_=nv_sr_srsg_3_tt_8_nm_0_in_0_q_girls%2520on%2520film] Clare Bateman-King at Lilac Grove Entertainment: [https://lilacgrove.com/] JoJo Dye at JJD Consultancy: [link: https://jjdconsultancy.com/] Jane Owen at Jane Owen PR: [https://janeowenpr.com/] The House of Oria: [https://www.thehouseoforia.com/] Sunny Pal at Astella: [https://www.instagram.com/astellajewellery/?hl=en] HLA Agency: [https://hlaagency.co.uk/] Films mentioned in this episode: Die, My Love, Lynne Ramsay Eleanor the Great, Scarlett Johansson The History of Sound, Oliver Hermanus Mastermind, Kelly Reichardt My Father's Shadow, Akinola Davies Pillion, Harry Lighton Romería, Carla Simón Sirât, Oliver Laxe Sorry Baby, Eva Victor Sound of Falling, Mascha Schilinski The Secret Agent, Kleber Mendonça Filho Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold, who also produced this episode Audio Editor: Benjamin Cook Intern: Hattie Morris Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Lella Erludóttur í Hlaðvarpinu hjá Óla Jóns Um Lellu Lella Erludóttir lýsir sér sem "konu margra hatta" - hún er markþjálfi, mannauðssérfræðingur og hefur reynslu sem markaðskona. Hún starfar nú sem sjálfstætt starfandi markþjálfi og segir markaðsþekkingu koma sér alltaf að notum, hvort sem það er í starfi eða daglegu lífi. Hvað er markþjálfun? Lella útskýrir markþjálfun sem sannreynda viðtalsaðferð þar sem markþjálfinn hýsir rýmið og stýrir ferlinu, en markþeginn stýrir viðfangsefninu. Markþjálfinn spyr kraftmiklar og ögrandi spurningar til að efla vitundarsköpun hjá markþeganum. Grundvallartrú markþjálfunar er að hver og einn markþegi sé hæfur, skapandi, úrræðagóður og hafi öll svörin innra með sér. Sérhæfing Lellu Lella hefur þrengt markhóp sinn og sérhæft sig í: * Starfstengdri markþjálfun * Loddaralíð (imposter syndrome) - þar sem fólk líður eins og það sé að feika það og óttist að aðrir komist að "hinu sanna" Hún rekur sex klukkustunda námskeið um loddaralíð og tekur fólk í markþjálfun sem glímir við þetta vandamál. Starfstengd tímamót Lella vinnur mikið með fólk sem er að upplifa starfstengd tímamót: * Þá sem vilja meiri ábyrgð eða fleiri verkefni * Fólk sem vill skipta um starf eða veit ekki hvað það vill gera * Þá sem eru að jafna sig eftir veikindi eða kulnun * Fólk sem flytur aftur til landsins Faglegar vottanir Lella tilheyrir ICF (alþjóðasamtökum markþjálfa) með PCC vottun, sem þýðir: * ACC: Grunnmenntun + 100 klukkustundir í markþjálfun * PCC: 175 klukkustundir menntun + 500 klukkustundir markþjálfun * MCC: Enn meiri menntun + 2.500 klukkustundir markþjálfun NBI huggreiningar Lella er vottuð til að gera NBI huggreiningar sem mæla hugsnið í fjórum flokkum: * Gulur: Skapandi, lausnamiðað, opinn * Rauður: Félagslegur, mannlegur, tengsl * Grænn: Verndandi, skipulagður * Blár: Raunsær, staðreyndamiðaður Þetta tæki er hægt að nota á einstaklinga og teymi til að skilja vinnustaðamenningu betur. Vinnustaðamenning Lella útskýrir vinnustaðamenningu sem það hvernig samskipti fara fram og ferlar virka í raun og veru - ekki bara það sem stendur á veggnum. Hún leggur áherslu á að vinna þurfi með menningu frá grunni og upp, og að bæði leiðtogar og starfsfólk þurfi að vinna sína vinnu. Jafnvægi vinnu og einkalífs Frekar en að tala um jafnvægi lítur Lella á það að vinna og einkalíf ættu að styðja hvort við annað - vera samofin þannig að hvort um sig veiti virði og næringu. Helstu viðskiptavinir Lella segist aðallega fá til sín konur á einhvers konar tímamótum sem eru í aðstæðum sem þeim líður ekki vel í og vilja breytingar en vita ekki hvað eða treysta sér ekki til að sækjast eftir tækifærum. Árangursdæmi Lella nefnir dæmi um konu sem kom til hennar með það í huga að þurfa að sitja í óþægilegu starfi næstu 30 árin. Eftir sex tíma í markþjálfun hafði konan skýra sýn á hvað hún vildi, sagði upp starfi sínu og fékk að lokum starf sem stjórnandi í fyrirtæki þar sem henni líður vel. Hvar finn ég Lellu? https://www.lella.is/ https://www.facebook.com/lella.markthjalfi https://www.linkedin.com/in/lellaerludottir/ https://www.instagram.com/lella.markthjalfi/ https://www.tiktok.com/@lella.markthjalfi Viðtalið sýnir hvernig markþjálfun getur hjálpað fólki að finna skýrleika, sjálfstraust og stefnu í starfi og lífi.

Host Anna Smith brings you an exclusive conversation with the women of Mission: Impossible – The Final Reckoning, recorded live at London's Ham Yard Hotel. This latest instalment in the high-octane Mission: Impossible franchise sees Ethan Hunt and the IMF team race against time to confront the Entity, a rogue artificial intelligence threatening global destruction. Joining Anna for this special panel are two talents at the heart of the action: Pom Klementieff, who takes on the role of Paris, and Angela Bassett, returning as Erika Sloane, the President of the United States. Together, they delve into the challenges of working on one of cinema's most physically demanding franchises, explore the critical role costume design plays in shaping their characters, and reflect on the powerful, real-world impact of casting a Black woman as the US president in a fictional universe. Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Alex Jones Sound recordist: Erin Millican House band: MX Tyrants This episode is in partnership with Netflix © HLA Agency

In 1924, a surgeon and a pathologist had a conversation about some patients with multiple bowel polyps. The pathologist, Dr Cuthbert Dukes, and the surgeon, Mr JP Lockhart-Mummery, noted that patients had a family history of bowel cancer and could have hundreds of colonic polyps. They, with the help of HRJ Bussey, set up the Polyposis Registry. The registry collected information about these patients and the families from 1918 to 1954. They found that patients developed polyps in childhood, the risk of affected children was 50%, and cancer took 15 years to develop from first diagnosis. This was clearly a familial disease. Today, we know this a Familial Adenomatous Polyposis or FAP. The genetic basis for this condition was identified in the 1980s and 1990s. Professor Sir Walter Bodmer led a team to map the location of the Adenomatous Polyposis Coli (APC) gene involved. This is the story of Familial Adenomatous Polyposis (FAP) Our special guests: Professor Sir Walter Bodmer is a professor of the Cancer and Genetics laboratory and Department of Oncology at Oxford University. Areas of research include: HLA, population genetics, Human Genome Project, and mapped the APC gene. He was knighted in 1986. Dr Tristan Rutland is an Anatomical Pathologists, recipient of the Konrad Muller RCPA Outstanding Teaching Award (2020), and recipient of the Resident Advocate Award from the College of American Pathologists. Dr Emelia Ip is a trained medical oncologist, staff specialist in cancer genetics, and co-chair of EviQ Adult Cancer Genetics Reference Committee. Help support us on our donation page.See omnystudio.com/listener for privacy information.

Í þættinum í dag ræða Ólafur og Andri um hið svonefnda "ástand" á Íslandi í seinni heimsstyrjöld: Ástarsambönd íslenskra kvenna og breskra og bandarískra hermanna, og afskipti íslenskra yfirvalda af því.Hernámið hafði gríðarlegar samfélagslegar breytingar í för með sér fyrir Ísland. Með komu hernámsliðsins 1940-1941 streymdu tugir þúsunda hermanna til landsins og þegar mest lét var fjöldi setuliðsmanna á Íslandi nær helmingur íbúafjöldans. Sambönd íslenskra kvenna og setuliðsmanna ollu siðferðilegri skjálftaöldu hjá elítunni, og ríkisvaldið brást við af hörku. Fylgst var með ungum konum, haldið var skrá yfir sambönd þeirra og gripið til harðra aðgerða samkvæmt sérstökum lögum sem sett voru. Mikið hefur verið fjallað um "ástandið" á síðastliðnum áratugum í íslenskri sagnfræði, ekki síst í tengslum við sögulegt réttlæti, og þá sérlega hin síðustu ár eftir að skjöl urðu aðgengileg sem varpa ljósi á mögulega einar umfangsmestu njósnir íslenskra yfirvalda um einkalíf borgaranna fyrr og síðar.Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

Við ræðum við stjórnanda hlaðvarpsins Ein pæling, Þórarinn Hjartarson. Hlaðvörp skipta æ meira máli í þjóðfélagsumræðunni og við ætlum að ræða við stjórnendur hlaðvarpa í Lestinni næstu vikurnar.

Í dag byrjum við þáttinn á umfjöllun um vímuefnaröskun, sem er einn alvarlegasti heilbrigðisvandinn sem við glímum við – samkvæmt Alþjóðaheilbrigðisstofnuninni. Röskunin er þó meðhöndlanleg og við eigum meðferðir sem virka – en röskunin einkennist ekki síst af bakföllum og hindranirnar sem blasa við þeim sem sækja sér meðferð eru margar. Erla Björg Sigurðardóttir, lektor í félagsráðgjöf og framkvæmdastýra á áfangaheimili fyrir konur, Helena Gísladóttir, dagskrárstjóri meðferðar Krýsuvíkursamtakanna og MA-nemi í félagsráðgjöf og Sara Karlsdóttir löggiltur áfengis og vímuefnaráðgjafi og dagskrárstjóri meðferðar hjá Hlaðgerðarkoti setjast hjá okkur og ræða um félagslega stöðu einstaklinga í langtíma meðferð vegna vímuefnaröskunar. Hvað á að gera við rafhlöðuna úr rafmagnsbílnum þegar hann er hættur að ganga? Rúnar Unnþórsson, prófessor í iðnaðar- og vélaverkfræði við Háskóla Íslands, leitar nú svara við því en búast má við að innan fárra ára hafi fallið til mikið af slíkum rafhlöðum sem vel gætu átt gott og farsælt framhaldslíf. Og í lok þáttar ætlar Helga Lára Þorsteinsdóttir, safnstjóri RÚV, að kíkja við og deila með okkur gullmola úr safni Ríkisútvarpsins. Tónlist úr þættinum: Bridgers, Phoebe - Motion sickness. Fleet Foxes - Battery Kinzie. Stuðmenn - Vorið.

In this star-studded episode, Anna Smith and co-founder Hedda Lornie Archbold delve into two exciting new films led by complex and captivating women. First, Anna chats with Julia Louis-Dreyfus and Geraldine Viswanathan, stars of Thunderbolts*—the latest Marvel Cinematic Universe film. Together, they discuss their first meeting, stepping into a superhero world alongside Florence Pugh and bringing depth and humour to their roles. Then, Hedda speaks with producer Rosie Fellner and actor Elizabeth Reaser about The Uninvited—a darkly funny and deeply poignant film that explores gender, aging, and identity in Hollywood. Reaser portrays Rose, a once-famous actress whose life is upended by a mysterious guest at a glamorous Hollywood gathering. The film also stars Walton Goggins, Lois Smith, Eva De Dominici, Pedro Pascal, and Rufus Sewell, and is writer-director Nadia Conners' debut feature. Thunderbolts* landed in UK cinemas 1 May 2025 The Uninvited is in UK cinemas 9 May 2025 http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Hattie Morris Audio editor: Benjamin Cook House band: MX Tyrants Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Our Lawyer, Jim Pocrass, assesses the lawsuit brought by Streetsblog Los Angeles editor Joe Linton. LA Metro has argued that because it's not the city, it doesn't have to make bike infrastructure when repaving city streets, as called for in ballot measure HLA. The agency claims it would have to destroy homes and buildings to both preserve parking and make space for bikes (3:40). The standoff between New York and the Federal government over congestion pricing, as told by Streetsblog NYC Editor Gersh Kuntzman (10:22). Bike JC's Vice President Tony Borelli, Trustees Emmanuelle Morgan and Deidre Newman, and bike maker Anke Irmscher on Jersey City's bike ecosystem and their place in it. (23:50).

In this episode Ethan, Nic, and Sully discuss the closure of Pike Place Market to cars, LA Metro's light rail expansion to LAX, and the idea of Freedom Cities. They explore housing challenges in cities like Baltimore and Philadelphia, the HLA lawsuit in Los Angeles, and the difficulty of making public transit profitable. The conversation highlights the importance of headways, accountability in urban planning, and balancing the roles of cars, transit, and AI in city governance.Send us a question: radiofreeurbanism@gmail.comPatreon: patreon.com/RadioFreeUrbanism Instagram: https://rb.gy/ezn9rzSully: https://www.youtube.com/@SullyvilleEthan: https://www.youtube.com/@climateandtransitNic: https://www.youtube.com/@nicthedoorLinksBest Side Cycling - Car Free Pike Place: https://www.youtube.com/watch?v=aVCvnZnqyEIFreedom Cities: https://tinyurl.com/2z8carjbHLA Lawsuit: https://www.streetsforall.org/blog/first-hla-lawsuit

VidRay deals with his son hitting milestones, and Ray becomes competitive. Brad never watched Free Willy. Chuck wonders what would overshadow Will Smith's Oscars Slap and bring him back to Hollywood dominance?Also: Edge of Tomorrow, the Cruel Intentions kiss, WWE's HLA, American Pie and ultimately - the death of the teen sex comedy.Video edit by Craig Depina@funbearablepod / funbearablepod.com-------------------------------This episode is brought to you by NARRAGANSETT BEER! Check out Narragansett Beer nationally and make sure to check out the new Narragansett brewery in Providence, RI if you're in the New England area!narragansettbeer.com / @gansettbeer-------------------------------#podcast #laugh #funny #movies

News: Healthy Streets LA, the ballot measure which requires Los Angeles to implement bike infrastructure every time city streets are repaved, is being ignored by the county's transportation agency, LA Metro. Taylor talks with the founder of Streets For All, Michael Schneider, who led the HLA campaign, and the Editor of Streetsblog LA, Joe Linton, who's now suing the city (1:33). It's been 100 years since the Los Angeles city council passed the ordinance which said that if you're walking you have to give right of way to drivers everywhere, except for particular crossings. New Mexico adopted the Stop as Yield Law for cyclists. Paris reduced speed limits on the Boulevard Périphérique from 70 to 50 km/hr, resulting in reduced traffic congestion, smoother traffic flow, fewer crashes, lower air pollution, and lower noise levels. https://www.apur.org/en/our-works/tracking-changes-boulevard-peripherique-and-green-belt-districts-october-2024-february-2025 London's Tweed Run ride is April 29. For National Autism Acceptance Month, Detroit's Neila Johnson has created the Cycling the Spectrum ride. Neila talks with Motown Trailblazers Bike Club President Reo Ramsey (24:35). Cross country solo cyclist Chris Casey tells the story of his ride across the U.S. (34:05). Bike Thought: The 85th Percent Rule, by Charles Marohn (54:36). Thanks Ted Rogers of BikinginLA.com.

Í þættinum í dag ræða Söguskoðunarmenn um samúræjana – stríðsmenn gamla Japans og táknmyndir japanskrar menningar. Samúræjarnir voru kjarninn í japönsku lénsskipulagi og áttu gullöld sína á  Tokugawa tímabilinu (1600–1868), þegar Japan var sameinað undir sterku miðstjórnarvaldi sjógúnanna. Þetta tímabil einkenndist af friði, einangrunarstefnu og blómaskeiði í menningu, listum og heimspeki. Samúræjarnir voru hermenn, aðalsmenn og embættismenn og gegndu lykilhlutverki í samfélagi þar sem heiður, hollusta og agi réðu ríkjum. Riddaralegur lífstíll og siðir samúræjanna byggði á bushidō, „leið stríðsmannsins“, og hafa þessir japönsku riddarar verið táknmynd hins forna Japans sem leið undir lok á 19. öld.Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

Andrés Magnússon og Stefán Einar Stefánsson ræða um hrakfarir ríkisstjórnarinnar frá þvi að hún tók við völdum fyrir þremur mánuðum, almennt um stöðuna í stjórnmálum, hvort að Stefán Einar sé að stefna að því að verða bæjarstjóri í Garðabæ, hvort að það sé nýtt vandamál fyrir ríkisstjórnina í vændum, hvernig stjórnarandstaðan mun standa sig, um óviðeigandi spjallgrúbbur og margt annað sem vert er að fjalla um á afmælis-bjórkvöldi Þjóðmála. Hlaðvarp Þjóðmála fagnar nú fjögurra ára afmæli og það er af nægu að taka.

In this special episode recorded at the Glasgow Film Festival, Jessica Lange joins Girls On Film host Anna Smith to reflect on her extraordinary career across stage and screen. She discusses her latest film, Long Day's Journey Into Night, which premiered at the festival, and shares insights into her rural Minnesota upbringing, early years studying mime in Paris, and her upcoming role as Marlene Dietrich. Jessica also revisits some of her most iconic roles, from portraying Frances Farmer in the heartbreaking biopic Frances to starring alongside Dustin Hoffman in the genre-defying comedy Tootsie. She also explores her more recent work on American Horror Story, which not only cemented her status as an acting legend but also introduced her to a new generation of fans. Beloved by Gen X and Gen Z alike, Jessica's performances continue to captivate audiences across film, television and stage. Acclaimed as one of the greatest actresses of her generation, Jessica is the 15th Oscar winner to appear on Girls On Film. The conversation was recorded on 1 March 2025. http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Alex Jones House band: MX Tyrants Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

As the organ transplant list continues to grow, experts in the transplant diagnostics industry are looking for ways to address the supply and demand challenges within the field. New tactics, like retransplantation and xenotransplantation, and new testing methods, such as HLA testing and transplant diagnostics, are being explored to boost transplant success rates and ensure more patients get the lifesaving transplants they need. As President of Thermo Fisher Scientific's transplant diagnostics division, Tina Liedtky is at the cutting edge of meeting this challenge. She's also passionate about addressing health equity issues, such as ingrained biases regarding gender and race, to help bridge the transplantation gap.Tina joined Meg for a fascinating discussion about the future of transplantation, closing 'the gap', and Thermo Fisher's recent award. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In this episode of Girls On Film, recorded at the 2025 Glasgow Film Festival, host Anna Smith is joined by co-founder and Executive Producer of the podcast, Hedda Lornie Archbold, to bring listeners exclusive interviews with some of the festival's stars. They welcome insights from Festival Director Allison Gardner, star of opening gala film Tornado, Kōki, and two of the creative minds behind The Extraordinary Miss Flower. Allison Gardner talks about her highlights of her final year leading the Glasgow Film Festival. Kōki, the rising star of Tornado, opens up about her role as the daughter of a Japanese puppeteer in John Maclean's thriller. And Emiliana Torrini and Caroline Catz dive into their work on The Extraordinary Miss Flower, a genre-blending love letter to love letters, set to Torrini's dreamy soundtrack. The Extraordinary Miss Flower will be released in the UK on 9 May 2025. Tornado will be available in cinemas from 23 May 2025. Glasgow Film Festival 2025 runs from 26 February to 9 March 2025. For more information on screenings and tickets, visit the Glasgow Film Festival website https://www.glasgowfilm.org/home March is International Women's Month, and this year also marks the 20th Anniversary of Birds Eye View Festival, now Reclaim the Frame, a charity championing women filmmakers. The festival will host a Weekender from 7–9 March 2025 at BFI Southbank and Regent Street Cinema, featuring events, screenings, and a special showing of Lollipop, which featured in episode 181 of Girls On Film. For more details, visit reclaimtheframe.org.Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Benjamin Cook House band: MX Tyrants Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Host Anna Smith brings you an exclusive conversation with Zoe Saldaña, Clément Ducol and Camille, recorded live at London's Charlotte Street Hotel following a screening of the 13 time Oscar-nominated and 12 time BAFTA-nominated film Emilia Pérez. Directed by Jacques Audiard, this genre-blending musical thriller tells the story of a lawyer who becomes entangled in the world of a cartel boss undergoing a dramatic personal transformation. Starring Karla Sofía Gascón, Zoe Saldaña, Selena Gomez and Adriana Paz, the film is generating awards buzz for its bold storytelling and powerful performances. Joining Anna for this discussion is Oscar-nominee Zoe Saldaña, who plays Rita in the film. She shares her experience collaborating with versatile French filmmaker Jacques Audiard on bringing to life the story of four Latina women, citing how refreshing it was to embody a flawed woman, the character of Rita. She's joined by Clément Ducol and Camille, the composers and songwriters behind the film's evocative soundtrack, who share insights into the five-year-long creative process of bringing Emilia Pérez's distinctive musical identity to life. This episode was recorded live on 31 January 2025 and is brought to you in partnership with Netflix. Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Alex Jones Sound recordist: Erin Millican House band: MX Tyrants This episode is in partnership with Netflix © HLA Agency

In this special episode recorded at the 2025 Girls On Film Awards, we celebrate the remarkable achievements of women and people of marginalised genders in the film industry. Hosted by co-founders of Girls On Film Anna Smith and Hedda Lornie Archbold, the evening features inspiring speeches, awards across 14 categories, and interviews with some standout guests. You'll hear highlights from the ceremony, including insights from Oscar-nominated directors Coralie Fargeat (The Substance) and Shiori Itō (Black Box Diaries) as well as Oscar-nominated Actress Karla Sofía Gascón (Emilia Pérez). Also in this episode, attendees reflect on the importance of women-led cinema and diverse voices in the industry. We also spotlight the sponsors and partners who made the event possible: our Gold Sponsors, CrewHQ and IMDb; our Silver Sponsor, Curzon; and our Bronze Sponsors, Netflix and Intimacy on Set. We are grateful for the support of our media partners Deadline, British Cinematographer magazine, and DDA, and to Lilac Grove Entertainment for sponsoring the reception. The awards celebrate the ongoing progress toward more inclusive storytelling, and this episode brings you right into the heart of the celebration. This episode is sponsored by Elstree Film Studios, who are celebrating their centenary in 2025. Full list of winners BEST FEATURE FILM The Substance BEST DOCUMENTARY FEATURE Black Box Diaries BEST PERFORMANCE IN A LEADING ROLE Marianne Jean-Baptiste (Hard Truths) BEST PERFORMANCE IN A SUPPORTING ROLE Danielle Deadwyler (The Piano Lesson) FEMALE FRIENDSHIP ON SCREEN All We Imagine as Light ENSEMBLE CAST Emilia Pérez THE GIRLS ON FILM ALLY AWARD SPONSORED BY IMDb Mike Leigh (Hard Truths) BEST CINEMATOGRAPHY SPONSORED BY CREWHQ Hélène Louvart AFC (La Chimera) BEST PRODUCTION DESIGN Judy Becker (The Brutalist) BEST COSTUME DESIGN Linda Muir (Nosferatu) BEST COMPOSER Abigail Barlow and Emily Bear (Moana 2) BEST PUBLICITY CAMPAIGN Universal (Wicked) ACTIVIST IMPACT AWARD Shiori Ito (Black Box Diaries) FEMALE ORGASM ON SCREEN SPONSORED BY INTIMACY ON SET Nicole Kidman (with Nicole Kidman, and later Harris Dickinson) (Babygirl) Full list of commendations ENSEMBLE CAST Chuck Chuck Baby BEST COMPOSER Isobel Waller-Bridge (Wicked Little Letters) BEST PRODUCTION DESIGN Gemma Jackson (Lee) BEST COSTUME DESIGN Rebecca Gore (Timestalker) Find out more here https://hlaagency.co.uk/category/projects/girls-on-film-awards/ Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Interns: Anna Swartz and Oli Fyne Sound recordist: Erin Macmillan Audio editor: Benjamin Cook House band: MX Tyrants © HLA Agency

Madam President and all-around Immunogenetics boss, Dr. Cathi Murphey joins the podcast to discuss recent CMS updates, guidance, and clarifications on HLA testing and personnel.

Anna Smith takes a closer look at the poignant, BAFTA-nominated Netflix documentary Daughters, co-directed by Natalie Rae and Angela Patton. The film intimately portrays the lives of four young Black women in the United States, navigating the emotional challenges of growing up with fathers who are incarcerated. Directors Natalie and Angela join Anna to discuss their eight-year journey bringing this powerful story to life, from filming during the pandemic to building an open and compassionate dialogue with the young women seen on screen, all culminating in the transformative Daddy Daughter Dance at the heart of the documentary. Angela Patton, CEO of Girls For A Change, shares her perspective on amplifying young women's voices, while Natalie Rae delves into the creative and emotional process of filming such a personal and moving story in this episode of Girls On Film. Daughters is available to stream on Netflix now. Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Emma Butt House band: MX Tyrants This episode is in partnership with Netflix © HLA Agency

For more information, visit https://thecirsgroup.com CIRS, or Chronic Inflammatory Response Syndrome, is an illness usually caused by your genes. But there are two different genetic based tests you can get! One to determine your Genetic HLA Haplotype, and one to see what genes are up or down regulated. Both inform your treatment to varying degrees, so today we want to help you understand which does what and whether these tests make sense for you. For more information, support, and resources in your own CIRS healing journey, visit TheCIRSGroup.com TIME STAMPS: 0:00 Intro and disclaimer 1:05 The confusion between genetic haplotypes vs GENIE tests 2:00 HLA Genetic Haplotypes: what is that? 4:08 Why HLA testing is important 5:04 HLA does not change, and you'll probably need help to figure out what it is 6:42 Autoimmune genes vs CIRS genes 8:08 What is the GENIE test? 8:50 When should you get the GENIE test? 9:55 GENIE shows the expression of genes 11:30 What the GENIE can tell you 11:50 How to interpret your GENIE (hint: get help) 13:37 When and whether to test if you are tight on funds HELPFUL LINKS: Buy Jacie's book (and leave a review!): https://a.co/d/1uYwP0q The CIRS Summit: http://thecirssummit.com/ MyHouseMakesMeSick HLA calculator: https://www.myhousemakesmesick.com/hlacalc/ Our GENIE test episodes: https://youtu.be/bCNp9qNqWWc?si=Y0naeyaEGVUXYm5W https://youtu.be/OoiT7WZ_UJI?si=s6aUTNO3iLf9fKvQ Order the GENIE here: https://www.progenedx.com/product-index Book a consultation with Christian to interpret your GENIE: https://cirslab.circle.so/checkout/11-with-christian The CIRS Group: Join our support community: https://thecirsgroup.com Check out our instagram: https://www.instagram.com/thecirsgroup/ Find Jacie for carnivore, lifestyle and limbic resources: Instagram: https://www.instagram.com/ladycarnivory YouTube: https://www.youtube.com/@LadyCarnivory Blog: https://www.ladycarnivory.com/ Order Jacie's book! https://a.co/d/8ZKCqz0 Find Barbara for business/finance tips and coaching: Website: https://www.actlikebarbara.com/ Instagram: https://www.instagram.com/actlikebarbara/ YouTube: https://www.youtube.com/@actlikebarbara Jacie is a Shoemaker certified Proficiency Partner, NASM certified nutrition coach, author, and carnivore recipe developer determined to share the life changing information of carnivore and CIRS to anyone who will listen. Barbara is a business and fitness coach, CIRS and ADHD advocate, speaker, and a big fan of health and freedom. Together, they co-founded The CIRS Group, an online support community to help people that are struggling with their CIRS diagnosis and treatment.

In this episode, Julia, Mason, and the former program assistant, now Water Conservation Educator, Andrew discuss the future of water conservation education with OK County OSU Extension. They also discuss how the Oklahoma City Water Utilities Trust (OCWUT), Oklahoma Department of Environmental Quality (OK-DEQ), and the Oklahoma Water Resource Board (OWRB) manage water. Related Fact Sheets: AGEC-1018: "Understanding the Different Kinds of Water Addressed by Oklahoma's Water Law" CR-1016: "Economic Impact of Conservation Dollars in Oklahoma" WREC-1017: "Considering Water Quality in Oklahoma" WREC-104: "Introduction to Groundwater Hydrology and Management" L-346: "Responsible Lawn Care" L-458: "Water-Wise Landscape Principles for Oklahoma" HLA-6615: "Simple Irrigation Checkup for Home Sprinkler Systems" BAE-1511: "Drip Irrigation Systems" BAE-1757: "Design of Rainwater Harvesting Systems in Oklahoma" PSS-2902: "What Soil, Forage, or Water Test Do You Need?" HLA-6444: "Drought Tolerant Plant Selections for Oklahoma"

On this special holiday episode, Julia, Andrew, and Mason discuss the history, care, and legends on the poinsettia. Related fact sheets and articles: HLA-6413: Poinsettia Care Poinsettias are a long-time holiday favorite Care for poinsettias during the holiday season

In today's episode, we welcome back Dr. Amar Kelkar for part 1 of our two-part discussion on allogeneic transplant. In this episode, we discuss the fundamental approach to patient selection and stem cell source selection. As you all know from this series, allogeneic transplants play a pivotal role in the management of AML. Dr. Kelkar's pearls of wisdom help make this confusing topic so much more approachable!Episode contents: - What factors do we incorporate when considering a patient for allogeneic transplant? - How do we use HLA-matching?- What are the pros and cons of the different sources of stem cells? ****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this episode, host Anna Smith transports listeners to the world of Wicked. She speaks with three key creatives behind this enchanting film adaptation of the hit Broadway musical. Directed by Jon M. Chu, the film stars Cynthia Erivo as Elphaba and Ariana Grande as Glinda, bringing this iconic story of friendship, magic, and love to life on the big screen. Hair, Makeup, and Prosthetics Designer Frances Hannon discusses how she approached creating Elphaba's iconic green look. Director of Photography Alice Brooks explains how she updated the technicolour dreamworld of Oz through the film's cinematography. And, Costume Designer Paul Tazewell describes how he developed a ‘language of clothing' to reflect the world and characters of Oz. The episode highlights the significant role that Hair and Makeup Design, Costume Design and Cinematography play in bringing the story of these two complex women to life. Listeners will get a glimpse into the artistry behind the film and the collaborative effort that makes Wicked both visually stunning and emotionally resonant. Wicked is in UK cinemas now, with part two coming next year. Let us know what you think on social media - tag Girls On Film and use the hashtag #WickedMovie. Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Emma Butt House band: MX Tyrants This episode is in partnership with Universal Pictures © HLA Agency

In this live Fertility Expert Q and A , I'm joined by Dr. Andrea Vidali. I had the honor of interviewing him about Pregmune, a platform for patients to receive a Reproductive Immunology work-up with him. We dove into the 6 categories that are part of a reproductive immunology work-up: HLA testing, NK activity, Systemic Inflammation, Thrombophilia, Regulatory T-cell, and Autoimmunity. It was so fascinating to learn from the best today. I hope you will listen in! Read the full show notes on Dr. Aimee's website. Pregmune's website. Subscribe to my YouTube channel for more fertility tips! Subscribe to the newsletter to get updates Do you have questions about IVF?Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, December 16th, 2024 at 4pm PST (7pm EST), where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom. Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.

Girls On Film brings you a live recording from the BFI's Art of Action season at the Exeter Phoenix Cinema in Devon. Host Anna Smith is joined by Priya Kansara, star of the genre-blending feminist action film Polite Society. Following a screening of Nida Manzoor's 2023 film, Priya discusses her lead role as Ria, a spirited young martial artist determined to stop her sister's wedding with an audacious heist. She describes how, despite their different heritages, she instantly identified with the character of Ria, and revealed how she worked with Manzoor to put a personal spin on the film's more comedic scenes. Priya also discusses the reality of finding a stunt double when you're a brown girl, calling for change in this area of the industry, as well as sharing some top tips for film industry newcomers to battle imposter syndrome. Listen to hear more! The conversation includes a post-screening Q&A with audience questions. This episode is part of Art of Action: Smash the Glass, a season that celebrates the women who have advanced action cinema both on and off-screen. The season is supported by National Lottery and BFI Film Audience Network with generous sponsorship from Packexe. To find out more about the BFI's Art of Action season, and, for our UK listeners, to see which films are screening near you, visit the British Film Institute website below. The season is running from October to December 2024. https://www.bfi.org.uk/art-action Also in this week's episode, Girls On Film is delighted to be celebrating our sixth birthday with the Female Film Club - a global members' club specifically for women in film - who are turning four. Together we share 10 years in the industry, and to mark the occasion Female Film Club are opening up their networking space to Girls On Film listeners who work the film industry: They offer a completely free networking space designed to help you make meaningful connections within the industry and to network with other members. With thousands of members in their database, you'll be joining a supportive community of creatives worldwide. With free membership, you'll get access to the FFC app, direct messaging with fellow members, and exclusive perks like special events and industry opportunities. It's a fantastic way to grow your network, build your skills, and get real support—some members have even landed jobs through it! https://female-film-club.mn.co/sign_up?bundle_token=e2f89f5961bbb9100aff796e6b36e50c&plan_id=479915&utm_source=manual” Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Benjamin Cook House band: MX Tyrants © HLA Agency

Nú um hegina kom út sex þátta röð frá einu þekktasta og virtasta hlaðvarpsfyrirtæki heims Serial, sem er hluti af New York Times fjölmiðlasamsteypunni. The Good whale sem fjallar um háhyrninginn Keikó. Hlaðvarpsþættirnir rekja sögu Keikós sem varð að alþjóðlegu tákni um illa meðferð á háhyrningum og hvölum almennt þegar hann lék í Hollywood-kvikmyndinni Free Willy árið 1993. Þá bjó hann i skemmtigarði í Mexíkó þar sem hann naut mikilla vinsælda en bjó við þröngan kost og slæma heilsu. Sú brjálæðislega hugmynd kviknaði að láta lífið líkja eftir listinni og reyna að koma dýrinu aftur út í náttúruna, gera húsdýrið villt aftur. Framkvæmdin var gríðarlega flókin, rándýr og umdeild. Keikó var fyrst fluttur til Oregon í Bandaríkjunum í hálfgerða endurhæfingu, og svo til Vestmannaeyja í september árið 1998. Í Lestinni í dag ætlum við að ræða við einn helsta þjálfara og umönnunaraðila Keikós á síðustu æviárum hans, Þorbjörgu Valdísi Kristjánsdóttur.

https://solvitryggva.is/ Vinirnir Helgi Jean Claessen og Hjálmar Örn Jóhannsson hafa í áraraðir verið að gera grínefni saman, en á löngum köflum gekk það brösulega. Hjálmar fór að vinna á leikskóla og Helgi fór í jakkaföt og vildi verða bissnessmaður. En dropinn holar steininn og í dag eru þeir í fullri vinnu við að gera grínefni, bæði í Hlaðvarpinu Hæhæ og Hjálmar fer í gervi Hvítvínskonunnar nær daglega. Hér ræða þeir Sölvi um mikilvægi þess að elta draumana, gefast ekki upp, hætta að láta álit annarra stýra sér og margt margt fleira. Þátturinn er í boði; Narfeyrarstofa - https://narfeyrarstofa.is/ Caveman - https://www.caveman.global/ H-Berg - https://hberg.is/ Nings - https://nings.is/ Myntkaup - https://myntkaup.is

Dr. Ryan Augustin and Dr. Jason Luke discuss neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, promising new TIL therapy for advanced melanoma, and the emerging role of CD3 engagers in treatment strategies. TRANSCRIPT Dr. Ryan Augustin: Hello, I'm Dr. Ryan Augustin, your guest host of the ASCO Daily News Podcast today. I'm a medical oncology fellow at Mayo Clinic in Rochester, Minnesota. Joining me today is Dr. Jason Luke, an associate professor of medicine and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center. I had the privilege of working as a postdoc in Jason's translational bioinformatics lab, where we investigated mechanisms of resistance to immunotherapy in melanoma and other cancers.  Today, we'll be discussing 3 important topics, including neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, the impact and practical considerations for incorporating TIL therapy into melanoma, and the current and future use of CD3 engagers in both uveal and cutaneous melanoma.  You'll find our full disclosures in the transcript of this episode.  Jason, it's great to have this opportunity to speak with you today. Dr. Jason Luke: Absolutely. Thanks, Ryan. It's great to see you. Dr. Ryan Augustin: So, to kick things off, Jason, we, of course, have seen tremendous advances in cancer immunotherapy, not only in metastatic disease but also the perioperative setting. Recent data have shown that the use of neoadjuvant therapy can provide not only critical prognostic information but can also help individualize post-resection treatment strategies and potentially even eliminate adjuvant therapy altogether in patients who achieve a pathologic, complete response. This signifies a conceptual shift in oncology with the goal of curing patients with immunotherapy. In triple-negative breast cancer, the KEYNOTE-522 regimen with pembrolizumab is standard of care. In non-small cell lung cancer, there are now four FDA approved chemo-IO regimens in both the neoadjuvant and perioperative settings. And, of course, in melanoma, starting with SWOG S1801 utilizing pembro mono therapy, and now with combined CTLA-4 PD-1 blockade based on results from the NADINA trial, neoadjuvant IO is the new standard of care in high-risk, resectable melanoma. It's important to highlight this because whereas other tumor types have more mature multidisciplinary care, for example, patients with breast cancer are reviewed by the whole team in every center, and every patient with lung cancer certainly benefits from multidisciplinary care conferences, that's not always the case with melanoma, given the relative frequency of cases compared to other tumor types.  Jason, would you say that we have now moved into an era where the integration of a multidisciplinary team and melanoma needs to be prioritized. And why is it important to have multidisciplinary team coordination from the onset of a patient's diagnosis? Dr. Jason Luke: Well, I think those are great questions, Ryan, and I think they really speak to the movement in our field and the great success that we've had integrating systemic therapy, particularly immunotherapy, into our treatment paradigms. And so, before answering your question directly, I would add even a little bit more color, which is to note that over the last few years, we've additionally seen the development of adjuvant therapy into stages of melanoma that, historically speaking, were considered low-risk, and medical oncologists might not even see the patient. To that, I'm speaking specifically about the stage 2B and 2C approvals for adjuvant anti-PD-1 with pembrolizumab or nivolumab. So this has been an emerging complication.  Classically, patients are diagnosed with melanoma by either their primary care doctor or a dermatologist. Again, classically, the next step was referral to a surgeon who had removed the primary lesion, with discussion around nodal evaluation as well. And that paradigm has really changed now, where I think integration of medical oncology input early on in the evaluation of the appropriate treatment plan for patients with melanoma is quite a pressing issue now, both because we have FDA approvals for therapeutics that can reduce risk of recurrence, and whether or not to pursue those makes a big difference to the patient for discussion early on.  And, moreover, the use of systemic therapies now, prior to surgery, of course, then, of course, requires the involvement of medical oncology. And just for an emphasis point on this, it's classically the case, for good reason, that surgeons complete their surgery and then feel confident to tell the patient, “Well, we got it all, and you're just in really good shape.” And while I understand where that's coming from, that often leaves aside the risk of recurrence. So you can have the most perfect surgery in the world and yet still be at very high risk of recurrence. And so it's commonly the case that we get patients referred to us after surgery who think they're just in totally good shape, quite surprised to find out that, in fact, they might have a 20% to 50% risk of recurrence. And so that's where this multidisciplinary integration for patient management really does make a big difference.  And so I would really emphasize the point you were making before, which is that we need multidisciplinary teams of med onc with derm, with surgery early on, to discuss “What are the treatment plans going to be for patients?” And that's true for neoadjuvant therapy, so, for palpable stage 3, where we might give checkpoint inhibitors or combinations before surgery. But it's true even in any reasonably high-risk melanoma, and I would argue in that state, anything more than stage 1 should be discussed as a group, because that communication strategy with the patient is so important from first principles, so that they have an expectation of what it's going to look like as they are followed out over time. And so we're emphasizing this point because I think it's mostly the case at most hospitals that there isn't a cutaneous oncology disease management meeting, and I think there needs to be.  It's important to point out that usually the surgeons that do this kind of surgery are actually either the GI surgeons who do colon cancer or the breast surgeons. And so, given that melanoma, it's not the most common kind of cancer, it could easily be integrated into the existing disease review groups to review these cases. And I think that's the point we really want to emphasize now. I think we're not going to belabor the data so much, but there are enormous advantages to either perioperative or adjuvant systemic therapy in melanoma. We're talking about risk reduction of more than 50%, 50-75% risk reduction. It's essential that we make sure we optimally offer that to patients. And, of course, patients will choose what they think is best for their care. But we need to message to them in a way that they can understand what the risks and benefits of those treatments are and then are well set up to understand what that treatment might look like and what their expectations would be out over time.  So I think this is a great art of medicine place to start. Instead of belaboring just the details of the trial to say, let's think about how we take care of our patients and how we communicate with them on first principles so that we can make the most out of the treatments that we do have available. Dr. Ryan Augustin: That's great, Jason. Very insightful points. Thank you.  So, shifting gears now, I'd also like to ask you a little bit about TIL therapy in melanoma. So our listeners will be aware that TIL is a promising new approach for treating advanced melanoma and leverages the power of a patient's cytotoxic T cells to attack cancer cells. While we've known about the potential of this therapy for some time, based on pioneering work at the NCI, this therapy is now FDA approved under the brand AMTAGVI (Lifileucel) from Iovance Biotherapeutics, making it the first cellular therapy to be approved for a solid tumor. Now, I know TIL therapy has been administered at your institution, Jason, for several years now, under trial status primarily for uveal melanoma using an in-house processing. But for many cancer centers, the only experience with cellular therapy has come under the domain of malignant hematology with CAR T administration. At our institution, for example, we have only recently started administering TIL therapy for melanoma, which has required a tremendous multidisciplinary effort among outpatient oncology, critical care, and an inpatient hematology service that has expertise in cytokine release syndrome.  Jason, where do you see TIL therapy fitting into the metastatic space? Which patients do you think are truly candidates for this intensive therapy? And what other practical or logistical considerations do you think we should keep in mind moving forward? Dr. Jason Luke: Well, thanks for raising this. I think the approval of lifileucel, which is the scientific name for the TIL product that's on the market now. It really is a shift, a landscape shift in oncology, and we're starting in melanoma again, as seems to be commonly the case in drug development. But it's really important to understand that this is a conceptually different kind of treatment, and therefore, it does require different considerations. Starting first with data and then actualization, maybe secondarily, when we see across the accelerated approval package that led to this being available, we quote patients that the response rate is likely in the range of 30%, maybe slightly lower than that, but a meaningful 25% to 30% response rate, and that most of those patients that do have response, it seems to be quite durable, meaning patients have been followed up to four years, and almost all the responders are still in response. And that's a really powerful thing to be able to tell a patient, particularly if the patient has already proceeded through multiple lines of prior standard therapy. So this is a very, very promising therapy.  Now, it is a complicated therapy as well. And so you highlighted that to do this, you have to have a tumor that's amenable for resection, a multidisciplinary team that has done a surgery to remove the tumor, sent it off to the company. They then need to process the TIL out of the tumor and then build them up into a personalized cell product, bring it back, you have to lympho-deplete the patient, re-introduce this TIL. So this is a process that, in the standard of care setting under best circumstances, takes roughly six weeks. So how to get that done in a timely fashion, I think, is evolving within our paradigms. But I think it is very important for people who practice in settings where this isn't already available to realize that referring patients for this should be a strong consideration. And thinking about how you could build your multidisciplinary team in a way to be able to facilitate this process, I think is going to be important, because this concept of TIL is relevant to other solid tumors as well. It's not approved yet in others, but we kind of assume eventually it probably will be. And so I think, thinking through this, how could it work, how do you refer patients is very important.  Now, coming back to the science, who should we treat with this? Well, of course, it's now an air quotes “standard of care option”, so really it ought to be available to anybody. I will note that currently, the capacity across the country to make these products is not really adequate to treat all the patients that we'd want. But who would we optimally want to treat, of course, would be people who have retained a good performance status after first line therapy, people who have tumors that are easily removable and who have not manifested a really rapid disease progression course, because then, of course, that six-week timeline probably doesn't make sense. The other really interesting data point out of the clinical trials so far is it has looked like the patients who got the least amount of benefit from anti-PD-1 immunotherapy, in other words, who progressed immediately without any kind of sustained response, those patients seem to have the best response to TILs, and that's actually sort of a great biomarker. So, this drug works the best for the population of patients where checkpoint inhibitors were not effective. And so as you think about who those patients might be in your practice, as you're listening, I think prioritizing it for primary progression on anti PD-1, again and giving it ahead thought about how would you get the patient through this process or referred to this process very quickly is really important because that lag time is a problem. Patients who have melanoma tend to progress reasonably quickly, and six weeks can be a long time in melanoma land. So, thinking ahead and building those processes is going to be important moving into the future Dr. Ryan Augustin: Definitely appreciate those practical considerations. Jason, thank you.  Moving on to our final topic, I was hoping to discuss the use of immune cell engagers in melanoma. So, similar to CAR T therapy, bispecific T-cell engagers, or BiTEs, as they're commonly known, are standard of care in refractory myeloma and lymphoma. But these antibodies engaging CD-3 on T cells and a tumor specific antigen on cancer cells are relatively new in the solid tumor space. Tarlatamab, which is a DLL-3 and CD-3 bispecific antibody, was recently approved in refractory small cell lung cancer, and, of course, tebentafusp, an HLA-directed CD-3 T cell engager was approved in uveal melanoma in 2022. Both T and NK cell engaging therapies are now offering hope in cancers where there has historically been little to offer. However, similar to our discussion with TIL therapy, bispecifics can lead to CRS and neurotoxicity, which require considerable logistical support and care coordination.  Jason, I was wondering if you could briefly discuss the current landscape of immune cell engagers in melanoma and how soon we may see these therapies enter the treatment paradigm for cutaneous disease. Dr. Jason Luke: I think it is an exciting, novel treatment strategy that I think we will only see emerge more and more. You alluded to the approval of tebentafusp in uveal melanoma, and those trials were, over the course of a decade, where those of us in solid tumor land learned how to manage cytokine release syndrome or the impact of these C3 bispecifics, in a way that we weren't used to. And what I'll caution people is that CRS, as this term, it sounds very scary because people have heard of patients that, of course, had difficult outcomes and hematological malignancies, but it's a spectrum of side effects. And so, when we think about tebentafusp, which is the approved molecule, really what we see is a lot of rash because GP100, the other tumor antigen target, is in the skin. So, patients get a rash, and then people do get fevers, but it's pretty rare to get more than that. So really what you have to have is the capacity to monitor patients for 12 hours, but it's really not more scary than that. So it really just requires treating a few people to kind of get used to these kinds of symptoms, because they're not the full-on ICU level CRS that we see with, say, CAR T-cells.  But where is the field going? Well, there's a second CD3 bispecific called brenetafusp that targets the molecule PRAME, that's in a phase 3 clinical trial now for frontline cutaneous melanoma. And tebentafusp is also being evaluated in cutaneous melanoma for refractory disease. So, it's very possible that these could be very commonly used for cutaneous melanoma, moving into, say, a two-to-four-year time horizon. And so therefore, getting used to what are these side effects, how do you manage them in an ambulatory practice for solid tumor, etc., is going to be something everyone's going to have to learn how to deal with, but I don't think it should be something that people should be afraid of.  One thing that we've seen with these molecules so far is that their kinetics of treatment effect do look slightly different than what we see with more classic oncology therapies. These drugs have a long-term benefit but doesn't always manifest as disease regression. So, we commonly see patients will have stable disease, meaning their tumor stops growing, but we don't see that it shrank a lot, but that can turn into a very meaningful long-term benefit. So that's something that we're also, as a community, going to have to get used to. It may not be the case we see tumors shrink dramatically upfront, but rather we can actually follow people with good quality- of-life over a longer period of time.  Where is the field going? You mentioned tarlatamab in small cell lung cancer, and I think we're only going to see more of these as appropriate tumor antigens are identified in different tumors. And then the other piece is these CD3 engagers generally rely upon some kind of engagement with a T cell, whether CD3 engagers, and so they can be TCR or T-cell receptor-based therapies, although they can be also SCFV-based. But that then requires new biomarkers, because TCR therapy requires HLA restriction. So, understanding that now we're going to need to profile patients based on their germline in addition to the genomics of the tumor. And those two things are separate. But I would argue at this point, basically everybody with cutaneous melanoma should be being profiled for HLA-A(*)0201, which is the major T-cell receptor HLA haplotype that we would be looking for, because whether or not you can get access immediately to tebentafusp, but therefore clinical trials will become more and more important.  Finally, in that T-cell receptor vein, there are also T cell receptor-transduced T cells, which are also becoming of relevance in the oncology community and people listening will be aware in synovial sarcoma of the first approval for a TCR-transduced T cell with afamitresgene autoleucel. And in melanoma, we similarly have TCR-transduced T cells that are coming forward in clinical trials into phase 3, the IMA203 PRAME-directed molecule particularly. And leveraging our prior conversation about TILs, we're going to have more and more cellular based therapies coming forward, which is going to make it important to understand what are the biomarkers that go with those, what are the side effect profiles of these, and how do you build your practice in a way that you can optimally get your patients access to all of these different treatments, because it will become more logistically complicated, kind of as more of these therapies come online over the next, like we said, two to four years kind of time horizon. So, it's very exciting, but there is more to do, both logistically and scientifically. Dr. Ryan Augustin: That's excellent. Thanks, Jason, and thank you so much for sharing your great insight with us today on the ASCO Daily News Podcast. Dr. Jason Luke: Thanks so much for the opportunity. Dr. Ryan Augustin: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode, and you can follow Dr. Luke on X, formerly known as Twitter, @jasonlukemd. And you can find me, @RyanAugustinMD. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers: @ryanaugustinmd Dr. Jason Luke @jasonlukemd   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures: Dr. Ryan Augustin: No relationships to disclose Dr. Jason Luke: Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

In this JCO Article Insights episode, Alexandra Rojek provides a summary on "Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors" by Schaffer et al published in the Journal of Clinical Oncology July 17th, 2024. TRANSCRIPT Alexandra Rojek: Hello and welcome to JCO Article Insights. I'm your host, Alexandra Rojek, and today we will be discussing an original report published in the October 1st issue of JCO titled, “Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors,” by Shaffer et al. The CIBMTR registry study set out to compare outcomes of patients undergoing allogeneic stem cell transplantation hematologic malignancies by HLA antigen matching status as well as by the type of GVHD prophylaxis regimen received either calcineurin inhibitor-based prophylaxis or post-transplant cyclophosphamide or PTCy. This study included patients reported to CIBMTR from January 2017 to June 2021 with AML, ALL or MDS, and required that they have undergone allotransplant with either a calcineurin inhibitor based so tacro or cyclosporine, GVHD prophylaxis, or PTCy, which included a calcineurin inhibitor or sirolimus with or without MMF and ATG. Matched unrelated donors were defined as an 8 out of 8 HLA match. And mismatched unrelated donors were defined as HLA mismatched at any single locus or 7 out of 8. The primary objective of the study aimed to compare overall survival or OS and GVHD and relapse-free survival (GRFS) within and between matched unrelated donors versus mismatched unrelated donors separated by calcineurin inhibitor versus PTCy based GVHD prophylaxis. GRFS was defined as survival without grade 3 to 4 acute GVHD, moderate to severe chronic GVHD requiring systemic therapy or relapse. 10,025 patients were included from 153 centers, with a median follow up of over 36 months. Mismatched unrelated donor recipients were made up of 22% minority ancestry patients as compared to just 8% of patients receiving a matched unrelated donor allo transplant, showing an enrichment for patients of minority ancestry in the mismatched unrelated donor group. Just under 10% of patients were of minority ancestry in the study overall, reflective of challenges in transplant care for these patients, which may include inferior access to care, fewer available and suitably matched donors, among other factors. 54% of all patients were transplanted for AML and 29% for MDS. 45% of patients received myeloablative conditioning, 25% received regimens containing ATG, and 23% overall received PTCy with either a calcineurin inhibitor or sirolimus as well as MMF. Among patients receiving PTCy, the authors did not find differences in overall survival by degree of HLA matching, whereas among patients receiving calcineurin inhibitor-based prophylaxis, there remained survival differences by HLA matching status. When comparing matched unrelated donor calcineurin inhibitor patients with PTCy matched unrelated donor patients, the PTCy arm had better OS, and the mismatched unrelated donor group who received PTCy had similar OS as well. For GRFS, matched unrelated donor and mismatched unrelated donor PTCy patients had no difference in GRFS, similar to the trend the authors see with overall survival. But these patients also had better GRFS than matched unrelated donor patients receiving calcineurin inhibitor-based prophylaxis. Within each prophylaxis arm, there was no difference in GRFS by HLA matching status. HLA mismatched patients receiving PTCy were less likely to experience GRFS than HLA mismatched patients receiving calcineurin inhibitor-based prophylaxis. The authors saw similar differences in comparative trends when subgrouping patients based on conditioning intensity and additionally did not find differences in GRFS and OS by ATG exposure. When looking at patients with minority ancestry, those patients who received a match unrelated donor or mismatched unrelated donor with PTCy had comparable outcomes to non-Hispanic white patients. Additionally, among minority ancestry patients, there was a significant benefit in both GRFS and OS in the PTCy groups as compared to calcineurin inhibitor-based prophylaxis. When examining other specific toxicities included in the composite GRFS endpoint, such as GVHD rates among PTCy patients, the authors note that patients receiving a matched unrelated donor had similar rates of grade 3 to 4 acute GVHD but lower rates of moderate to severe chronic GVHD requiring systemic therapy. There appears to be signal that among PTCy patients, HLA matching reduced rates of moderate to severe chronic GVHD compared to mismatched unrelated donor patients receiving PTCy. These same trends also held when the authors looked at non relapse mortality with no significant differences within the PTCy groups by HLA matching status but reduced non relapse mortality compared to both calcineur and inhibitor-based groups. However, notably, there was a greater risk of relapse among matched unrelated donor PTCy patients than matched unrelated donor calcineurin inhibitor patients, although this risk was comparable between mismatched unrelated donor patients by type of prophylaxis. The authors note that this has also been observed in other retrospective cohorts and may be confounded by differences in conditioning intensity between these cohorts of matched unrelated donor patients, affecting the risk of relapse. Finally, the authors also evaluate whether expansion of donor search criteria to mismatch donors from full HLA matching would increase availability of young donors from minority ancestry patients, and the study noted striking increases for all subgroups examined. This study fits nicely with the BMT CTN 1703 trial published in the recent past, which has showed the superiority of PTCy with the calcineurin inhibitor and MMF when compared with conventional calcineurin inhibitor based immune prophylaxis for reduced intensity matched related donor and matched unrelated donor allotransplant. Of note, very few patients with one HLA antigen mismatch were enrolled on that study. However, others have shown the feasibility of PTCy in the mismatched unrelated donor setting, which has led to its adoption in practice. Although less than a quarter of patients included in this current study received PTCy overall, the findings clearly are aligned with the BMT CTN 1703 study, which is likely to change clinical practice in the longer term in this field. As the accompanying editorial in JCO, written by Dr. Chakravarty nicely lays out, the differences between this study and the EBMT registry study, also published in this issue of JCO are subtle but worthy of note. While both studies show that mismatched unrelated donor patients had worse OS and GRFS than those receiving matched unrelated donor transplants, and then among matched unrelated donor patients the addition of PTCy improved GRFS and OS, there is discordance between the studies whether the addition of PTCy abrogates the effect of HLA mismatching on GRFS and OS. As this editorial points out, there are strikingly different rates of T cell depletion with ATG between the US and Europe, which may account for differences in comparator arms that lead to this discordance. There are several very exciting clinical trials ongoing that will aim to answer some of these outstanding questions regarding comparisons of PTCy and T cell depletion, which the field eagerly looks forward to reviewing. In summary, this registry study of patients receiving allo transplant with matched unrelated donor or mismatched unrelated donor and calcineurin inhibitor or PTCy based GVHD prophylaxis, most notably shows that for patients who may not have a matched unrelated donor available, the addition of PTCy to a mismatched unrelated donor allo transplant allows for improved outcomes after transplant in toxicities and survival. This is most significant for patients of minority ancestries who usually have fewer matched unrelated donors available in registry searches. Improving the transplant options available to these groups of patients is of critical importance in improving equitable access to care for all of our patients. And this study, although retrospective in nature, provides an important understanding of our progress to date and suggests directions for future investigation may indeed be very feasible to continue to close these gaps in care for patients in need of an allo transplant for hematologic malignancies. This is Alexandra Rojek. Thank you for listening to JCO Article Insights. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

 Hal Gill from Preds Radio Network joins the show to talk Preds. Hal previewed tomorrow night's game against the Blackhawks. Hla also shared his thoughts on the new call-up Zach L'Heureux. Listen to hear more.

Framtíð Åge Fridtjof Hareide, lokaleikirnir í Bestu, enski og KFA tíminn gerður upp. Hlaðvarpsstjórnandinn Mikael lætur gamminn geisa, umsjón hafa Helgi Fannar og Keli.

Núna tel ég réttast að kveðja formlega hlaðvarpið Karlmennskan. Reyndar munu bakhjarlar sjá til þess að það verði áfram opið og aðgengilegt en ég mun ekki taka upp fleiri þætti. Það hefur verið afskaplega gaman að hitta og spjalla við svo margt frótt fólk með áhugaverða reynslu eða sjónarhorn á samfélagið. Markmiðið var alltaf að varpa ljósi á virkni feðraveldis í gegnum mismunandi birtingamyndir, sem höfðu einhvern snertiflöt við karla eða karlmennsku. Veit að það tókst oft vel upp. Og það gleður mig að vita að ennþá eru nokkur hundruð einstaklingar að hlusta á gamla þætti. Takk öll sem hlustuðuð. Takk öll sem gáfu tíma ykkar, reynslu og þekkingu í hlaðvarpinu.   P.S. Þau ykkar sem þráið meira af svipuðu efni getið gerst áskrifendur að vikulega hlaðvarpinu Sópað undan teppinu með Þorsteini V. og Huldu Tölgyes. Hlaðvarpið er að finna á þriðja.is

HLA Director and Transfusion Medicine Specialist, Dr. Ryan Pena, joins Coffee & Compatibility to discuss how HLA laboratories can support transfusion medicine specialists. From HLA typing to anti-HLA antibody analysis in this niche service, Dr. Pena breaks it all down.

Why You Should Listen:  In this episode, you will learn about the use of GENIE testing in Chronic Inflammatory Response Syndrome. About My Guest: My guest for this episode is Dr. Ritchie Shoemaker.  Ritchie Shoemaker, MD is a recognized leader in patient care, research, and an education pioneer in the field of biotoxin related illness.  While illness acquired following exposure to the interior environment of water-damaged buildings (WDB) comprises the bulk of Dr. Shoemaker's daily practice, other illnesses caused by exposure to biologically-produced toxins are quite similar in their “final common pathway.”  What this means is that while the illness might begin acutely with exposure to fungi, spirochetes, apicomplexans, dinoflagellates and cyanobacteria, for example, in its chronic form, each of these illnesses has similar symptoms, lab findings, and Visual Contrast Sensitivity (VCS) findings.  Taken together the inflammatory illness from each of these diverse sources is known as  Chronic Inflammatory Response Syndrome. Key Takeaways: What is GENIE? Is HLA-DR still relevant? What are the common triggers of CIRS?  Actinobacteria?  Endotoxins?  Mold and mycotoxins? What is hypometabolism? How does CIRS impact insulin and blood sugar? What is apoptosis? What is the role of coagulation in CIRS? Are upregulated cytokines seen in CIRS? Can GENIE identify those that may have Lyme? What are defensins? What is Ikaros? What is the role of MAP kinases in CIRS? What do Toll receptors tell us? How are B and T cells involved in CIRS? How many CIRS markers are needed in GENIE to suggest CIRS? What is the PTSD gene? How often is histamine involved? What are the cytoskeleton and microtubules?  What can be determined around the function of Treg cells? What are the recent additions to GENIE in the realm of Parkinson's disease? What has GENIE told us about MARCoNS? Connect With My Guest:  http://SurvivingMold.com Interview Date: September 11, 2024 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode205. Additional Information: To learn more, visit https://BetterHealthGuy.com. Disclaimer:  The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority. 

In this CLASSIC episode of the Ruthlessly Aggressive Podcast, to get ready for the 2003 edition of Unforgiven, Jake Williams is joined by Scott Shifflet to discuss Unforgiven 2002. The duo discuss a fun eight man opener, Flair getting fooled by Jericho, Three Minute Warning's in ring debut, a disappointing performance from Van Dam and Triple H, Bischoff's HLA plans getting foiled, the Lesnar/Undertaker showdown, and much more. Follow along through this progression through aggression!

Dr. Gerald Morris, the current Chair of the OPTN Histocompatibility Committee, joins Coffee & Compatibility to discuss upcoming changes in HLA testing and nomenclature, and their potential impacts on organ allocation in the United States.

In this episode, we dive into the critical role of HLA gene variants, such as HLA-DRB1, and their profound impact on immune system function, particularly focusing on their significance in conditions like Lyme disease and mold toxicity. We'll explore how variations in these HLA genes, like the HLA-DRB1*0401 allele, influence the body's ability to recognize and respond to pathogens, potentially leading to chronic symptoms. The discussion will also cover HLA gene variant testing and how it can lend insight when it comes to taking a bioindividual approach to supporting the immune system. Topics: 1. Introduction - Explanation of HLA gene variants - Importance of HLA genes in immune system function 2. Basics of Genetics and Immunology - What is a chromosome? - Introduction to genes and their functions - Overview of DNA and protein synthesis 3. Major Histocompatibility Complex (MHC) - Description of the Major Histocompatibility Complex - Division of MHC genes into Class I, II, and III - Role of Class I MHC genes in antigen presentation - Role of Class II MHC genes in antigen presentation - Function of Class III MHC genes 4. HLA Genes and Immune Function - Explanation of Human Leukocyte Antigen (HLA) genes - Connection between MHC genes and HLA genes (human MHC) - Transcription and regulation of HLA genes - Response to internal and external signals - Role of Antigen-presenting cells (APCs) 5. Pathogen Recognition and Immune Activation - Mechanism of pathogen recognition by HLA genes - Activation of immune response by antigen presentation - Formation and function of peptide-HLA complexes 6. Impact of HLA Variants on Disease - Specific focus on Lyme disease and mold toxicity - Role of HLA Class II alleles in immune response - Association of HLA-DR alleles with chronic Lyme disease - Sensitivity to mold exposure linked to certain HLA gene variants 7. Testing and Implications of HLA Gene Variants - Importance of HLA gene variant testing - Broader implications for diseases like lupus and multiple sclerosis - Personalized approaches based on HLA gene variants 8. Biotoxin Illness and Poor Antigen Presentation Due to an HLA Gene Variant - Strategies to support immune system function in the presence of biotoxins - Importance of detoxification pathways and binders Thank you to our episode sponsor: ⁠⁠⁠⁠⁠Liver Medic⁠⁠⁠⁠⁠⁠ Use code Chloe20 to save 20% on ⁠⁠⁠⁠⁠⁠⁠"Leaky Gut Repair"⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠Brendan's YouTube Channel⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠https://x.com/livermedic⁠⁠⁠⁠⁠⁠⁠ Thanks for tuning in! Get Chloe's Book Today! "⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠75 Gut-Healing Strategies & Biohacks⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠" Follow Chloe on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@synthesisofwellness⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow Chloe on TikTok @chloe_c_porter Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠synthesisofwellness.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to purchase products, subscribe to our mailing list, and more! --- Support this podcast: https://podcasters.spotify.com/pod/show/chloe-porter6/support

Chuck Staton and Brad Roeher of Funbearable chat it up with Codex Prime in this week's episode about everything from weird/bad dates, HLA, and more! Victor also showcases his latest haul from the Barnes & Noble July Criterion Collection sale, Carl highlights the new Sandra Bullock Netflix film Unforgivable and the new Beverly Hills Cop sequel Axel F., and Victor also highlights the new films Monkey Man and Late Night with the Devil. We believe in Joe Hendry, so let's GET IT! Recorded July 9, 2024 ---------------------------------------------------------------------------------- Catch Codex Prime on Spotify, Apple Podcasts, or other podcast platforms. Email: CodexPrimePodcast@gmail.com SOCIAL MEDIA: Facebook: www.facebook.com/codexprime Twitter: twitter.com/codexprimecast Instagram: instagram.com/codexprimepodcast/ YouTube: www.youtube.com/channel/UCbDMNJNgnM6y3WB3fA1a1HA SoundCloud: @codex-prime Victor Omoayo - Do the Film Thing Podcast: https://dothefilmthing.podbean.com/ - Do the Film Thing Linktree: https://linktr.ee/dothefilmthing - Email: dothefilmthing@gmail.com Carl Byrd - Twitter, Instagram, TikTok and Mixcloud @mrbyrd1027